SCHEDULE: Paradigm BioCapital takes 8.6% stake in Vor Bio

Paradigm BioCapital and affiliates report beneficial ownership of 1.75M Vor Biopharma shares (8.6%) via a passive Schedule 13G.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. report beneficial ownership of Vor Biopharma common stock under Schedule 13G.
• Paradigm BioCapital Advisors LP, its GP, and Senai Asefaw each report 1,750,000 shares beneficially owned with sole voting and dispositive power (8.6% of the class) and no shared power.
• Paradigm BioCapital International Fund Ltd. directly owns 1,546,061 shares with sole voting and dispositive power (7.6% of the class).
• Ownership percentages are calculated on 20,410,630 shares outstanding, based on 10,410,630 shares outstanding as of November 7, 2025 and an additional 10,000,000 shares issued pursuant to a Prospectus Supplement filed November 12, 2025.
• The reporting persons certify the holdings are not for the purpose of changing or influencing control (passive investment).
• Date of event requiring the filing: November 11, 2025; signatures and joint filing agreement dated November 18, 2025.

Sentiment

Score: 6

Explanation: Neutral-to-positive: a respected specialist fund disclosed a sizable passive stake, and the updated share count reflects recent capital markets activity; no operational or financial performance data provided.

Positives

• A specialist healthcare investor (Paradigm BioCapital) disclosed an 8.6% passive stake, adding institutional sponsorship.
• Sole voting and dispositive power over 1,750,000 shares provides clarity on governance influence without shared control.
• Ownership calculations transparently incorporate the issuer’s recent 10,000,000-share issuance, reflecting the updated share count.

Negatives

• A single investor controls 8.6% of the company’s common stock, indicating meaningful ownership concentration.
• The referenced 10,000,000 new shares increase outstanding share count, implying dilution for existing holders.

Future Outlook

No forward-looking statements or guidance are provided; the investors certify a passive intent with no purpose of changing or influencing control.

Industry Context

Specialist biotech funds frequently report 5–10% passive stakes via Schedule 13G, signaling sector-focused sponsorship without activist intent. Such disclosures often follow capital raises that expand float and liquidity.

Comparison to Industry Standards

• An 8–9% passive stake aligns with common positions taken by specialist healthcare funds in small/mid-cap biotech, comparable to non-activist holdings often disclosed by firms like RA Capital, Baker Bros., or Perceptive Advisors.
• Using the post-offering share count to compute ownership is standard practice; including the 10M new shares in the denominator is consistent with SEC reporting norms after follow-on offerings.

Stakeholder Impact

• Shareholders gain visibility into a new 5%+ institutional holder (Paradigm BioCapital), which can support market confidence.
• Float and liquidity are higher following the referenced 10,000,000-share issuance.
• The passive 13G certification indicates no current intent by the holder to influence corporate control.

Key Dates

Keywords

Schedule 13G, Vor Biopharma, Paradigm BioCapital, beneficial ownership, 8.6% stake, Senai Asefaw, biotech, VOR, Common Stock, CUSIP 929033207, institutional investor, passive investor